Results 171 to 180 of about 79,696 (205)
Some of the next articles are maybe not open access.
Prescribing of Phosphodiesterase-5 Inhibitors Among Psychiatrists
Journal of Sex & Marital Therapy, 2013Phosphodiesterase-5 (PDE-5) inhibitors—avanafil, sildenafil, tadalafil, and vardenafil—are approved and widely used for treatment of erectile dysfunction of various etiologies.
Richard, Balon +2 more
openaire +2 more sources
Phosphodiesterase-5 inhibitors and their hemodynamic effects
Current Hypertension Reports, 2006Erectile dysfunction occurs commonly in untreated and treated hypertensive patients, impairing adherence to treatment and quality of life. Furthermore, it is a marker for enhanced risk for cardiovascular disease. Phosphodiesterase type 5 (PDE5) inhibitors, sildenafil, vardenafil, and tadalafil, provide effective treatment of erectile dysfunction.
openaire +2 more sources
Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia
Current Opinion in Urology, 2010Benign prostatic hyperplasia (BPH) is prevalent in old men and often results in lower urinary tract symptoms (LUTS). Phosphodiesterase-5 (PDE5) inhibitors increase intracellular concentrations of cyclic guanosine monophosphate. PDE5 inhibitors (sildenafil, tadalafil, vardenafil, etc.) are first-line treatments for erectile dysfunction.
openaire +2 more sources
Phosphodiesterase 5 inhibitors in male sexual dysfunction
Current Opinion in Urology, 2003Phosphodiesterase 5 inhibitors are preferred by most men for the oral treatment of erectile dysfunction. In many guidelines, this therapy is recommended as first-line therapy because of convenience, high efficacy, and low rates of side-effects. Sildenafil was the first drug for the treatment of erectile dysfunction, introduced in 1998.
openaire +2 more sources
Phosphodiesterase‐5 Inhibitors and Migraine
Headache: The Journal of Head and Face Pain, 2004Evans, Randolph W +1 more
openaire +3 more sources
Phosphodiesterase 5 inhibitors in vascular systemic disorders
Joint Bone Spine, 2012Joint Bone Spine - In Press.Proof corrected by the author Available online since dimanche 11 mars ...
openaire +2 more sources
Pharmacology of phosphodiesterase 5 inhibitors.
The Canadian journal of urology, 2003The phosphodiesterase enzymes, of at least 11 types, are ubiquitous throughout the body, and perform a variety of functions. Phosphodiesterase type 5 (PDE5) is the predominant enzyme in the corpus cavernosum, and plays a crucial role in penile erection.
openaire +1 more source
Phase 4 Studies on Phosphodiesterase 5 Inhibitors
JAMA Ophthalmology, 2022Brian L, VanderBeek, Maureen G, Maguire
openaire +2 more sources
Phosphodiesterase 5 (PDE5): Structure-function regulation and therapeutic applications of inhibitors
Biomedicine and Pharmacotherapy, 2021Wesam S Ahmed, Anupriya
exaly